Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-09-28
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines for severe diseases, led by CASGEVY and a pipeline spanning cardiometabolic, autoimmune, oncology, and regenerative medicine programs.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From First Approval to Repeatable Franchise
The key question is whether one historic approval becomes a durable multi-asset business. A steady CASGEVY ramp plus one launch-visible owned program can support a meaningful rerating, but the path still runs through hard clinical and access bottlenecks.

Analysis

Thesis
CRISPR Therapeutics can roughly double to triple over five years if CASGEVY proves durable as a real commercial anchor and at least one wholly owned follow-on asset becomes launch-visible, shifting the story from single-asset validation to repeatable platform value capture.
Last Economy Alignment
AI helps this company generate and prioritize more biological shots on goal, but value still depends on hard bottlenecks that software cannot erase: clinical proof, manufacturing, reimbursement, and regulation. Low software commoditization and low agent bypass risk support a positive score, yet biology keeps the upside from looking software-like.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
The upside case is not broad platform magic; it is a specific transition from first approval to repeatable value capture. CASGEVY can keep building regulatory trust and commercial credibility, while one owned or economically better-retained follow-on asset would let investors underwrite direct product economics instead of distant optionality alone. That combination can justify a meaningful rerating, but access complexity and clinical proof still cap the outcome well below hypergrowth territory.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not survival; it is proof conversion. CRISPR Therapeutics must show that first approval can translate into repeatable approvals, better-controlled economics, and scalable manufacturing and access. If late-2026 and 2027 readouts disappoint, the market is likely to fall back to valuing cash, CASGEVY optionality, and a discounted platform rather than a multi-franchise growth story.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.32
They control valuable biology, IP, and some manufacturing know-how, and AI should help them create more good drug ideas faster. But the real bottlenecks are still human and physical: proving safety and durability, getting regulators comfortable, and moving patients through a complex treatment system.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$87.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case